Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Sep 11, 2011 3:20 PM Flag

    Phase 1 MTC data review: question , Pt 1

    I grabbed the following from the 7/6/11 EXEL Cabo update. This is the same news release that announced the 3 month delay of MTC P3 results...

    "The phase 1 trial enrolled a total of 37 patients with 35 patients being response evaluable. It showed a 29% rate of confirmed partial responses. These responses were generally durable with a response duration of up to 48+
    months per the most recent update. Four patients are in continued response at the
    current time. Additionally, 15 patients (41%)
    had stable disease lasting longer than 6
    months with some patients continuing on study
    3+ years after study initiation. Activity was
    independent of both RET mutation status and
    prior treatment with tyrosine kinase inhibitors,
    including vandetanib."

    I find the last sentence both compelling and intriguiging. Does the specific inclusion of comparison to Vandetinib suggest that Cabo is a better therapeutic agent, or simply that it has shown to favorably react where Vandetinib has not?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ...later treated w/ CABO. Activity noted. Interesting, no?
      My conjecture is that either the AE was too stressful...or the vandetanib less than effective... Is it a sound inference to suggest that-for some patients-CABO may prove to be a best,if only more effective choice.
      Conversely, I have been looking for a former CABO recipient...currently treated w/ vandetanib. I can find no evidence of this...
      Anyone...?

 
EXEL
2.83+0.26(+10.12%)May 1 4:00 PMEDT